BRD2 and obesity due to melanocortin 4 receptor deficiency: These initial proof-of-concept studies have paved the way for treatment of 3 disorders of public health magnitude — osteoporosis, obesity, and AD — simultaneously and with a single FSH inhibitor (3, 6, 7, 9, 10, 12, 29).